Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
Article Date
August 15, 2023
This article is featured on another website.
Go to article
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…